- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | JPM26: Eli Lilly reportedly eyes €15bn takeover of Abivax | ||
| Mo | FDA increases manufacturing flexibility for cell and gene therapies | ||
| Mo | JPM26: Revolution Medicines in spotlight as industry gears up for dealmaking spree | ||
| Mo | Novartis to build fourth US radioligand therapy facility in Florida | ||
| Mo | MediLink and Roche announce exclusive licensing agreement for YL201 | ||
| Fr | Alveus debuts in obesity arena with $160m Series A | ||
| Fr | J&J cuts MFN deal with the Trump administration, bolsters US onshoring efforts | ||
| Fr | Takeda and Halozyme sign global agreement for Enhanze technology | ||
| Fr | Santhera grants Agamree rights to Nxera for DMD | ||
| Do | Eli Lilly acquires inflammatory specialist Ventyx for $1.2bn | ||
| Do | GSK to file for approval of twice-yearly hep B drug on positive Phase III data | ||
| Do | Octapharma receives FDA approval for new Fibryga formulation in AFD | ||
| Do | Day One concludes Mersana Therapeutics acquisition | ||
| 07.01. | Amgen buys Dark Blue Therapeutics in $840m oncology deal | ||
| 07.01. | Eli Lilly signs $1.3bn obesity-focused research deal with Nimbus | ||
| 07.01. | Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis | ||
| 07.01. | Zai Lab's Augtyro receives NMPA approval for solid tumours in China | ||
| 06.01. | CDC shrinks childhood vaccine recommendation list to mirror "peer nations" | ||
| 06.01. | Takeda and Protagonist seek FDA approval for rusfertide to treat PV | ||
| 06.01. | Aktis Oncology kicks 2026 IPO cycle off with $210m target | ||
| 06.01. | Arrowhead receives Health Canada authorisation for Redemplo to treat FCS | ||
| 05.01. | Sanofi and Earendil Labs forge $2.56bn autoimmune deal | ||
| 05.01. | Insilico and Servier announce $888m oncology research agreement | ||
| 05.01. | Biogen's Tysabri to be used on England's NHS for highly active MS | ||
| 05.01. | Samsung Bioepis initiates Byooviz commercialisation in Europe |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .